Immunai Inc., an artificial intelligence (AI) biotech company specializing in mapping the human immune system, has entered a multi-year collaboration with Teva Pharmaceuticals, an affiliate of Teva Pharmaceutical Industries Ltd., under which it will collaborate with Teva in Immunology and Immuno-oncology programs.
 
This collaboration will leverage Immunai’s proprietary immune cell atlas, AMICA, and its AI model, the Immunodynamics Engine (IDE), to enhance clinical decision-making in Teva’s Immunology trials. Key focus areas will include drug mechanism of action, dose selection, and biomarker analyses.
 
“This collaboration reflects our ongoing efforts in enhancing drug development within immunology and immuno-oncology. Bringing a drug to market is inherently challenging, time-consuming, and costly,” said Noam Solomon, Ph.D., CEO of Immunai. “Through our partnership with Teva, we are eager to utilize our AI-based engine, the Immunodynamics Engine (IDE), to streamline this process and facilitate the delivery of new therapies to patients.”
 
“At Teva, we are always looking to unlock what’s next in science and working with Immunai to harness the power of their cutting-edge tools and AI solutions will help us to step up innovation to drive forward our research and development strategy,” said Eran Harary, MD, Senior Vice President of Global Early Clinical Development at Teva. “This collaboration will provide important insights into patient responses and treatment mechanisms in immunology and immuno-oncology, allowing us to optimize our clinical trials and improve outcomes for patients.”
 
The partnership also includes the potential for expanding the collaboration to encompass broader aspects of Teva’s research and development portfolio.

More Immunai News